Abstract
Ferumoxytol is a parenteral iron therapy that the Food and Drug Administration recently approved for the treatment of iron-deficiency anemia. The form of the iron, ultrasmall superparamagnetic iron oxide nanoparticles, causes T1, T2, and T2* shortening on magnetic resonance imaging, which can mimic hemosiderosis. We report such a case, with laboratory findings that demonstrate normal iron stores, and discuss the potential implications.
MeSH terms
-
Adrenal Glands / metabolism*
-
Adrenal Glands / pathology
-
Bone Marrow / metabolism*
-
Bone Marrow / pathology
-
False Positive Reactions
-
Female
-
Ferrosoferric Oxide / pharmacokinetics*
-
Hemosiderosis / diagnosis
-
Humans
-
Iron / blood
-
Liver / metabolism*
-
Liver / pathology
-
Liver Function Tests
-
Magnetic Resonance Imaging / methods*
-
Middle Aged
-
Parenteral Nutrition Solutions / metabolism
-
Spleen / metabolism*
-
Spleen / pathology
Substances
-
Parenteral Nutrition Solutions
-
Iron
-
Ferrosoferric Oxide